Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Monday. The stock traded as low as $4.67 and last traded at $5.3140, with a volume of 5934 shares. The stock had previously closed at $5.27.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on IMMP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prima BioMed in a research report on Friday, July 10th. Maxim Group upgraded Prima BioMed from a “hold” rating to a “buy” rating in a research note on Wednesday, June 17th. Finally, Jefferies Financial Group upgraded Prima BioMed from a “hold” rating to a “strong-buy” rating in a report on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $110.00.
Read Our Latest Stock Analysis on Prima BioMed
Prima BioMed Trading Down 2.1%
Prima BioMed (NASDAQ:IMMP – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter. The firm had revenue of $3.68 million during the quarter.
Prima BioMed Company Profile
Prima BioMed Limited was an Australian biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.
Its lead development program was eftilagimod alpha, also known as IMP321, a soluble LAG-3 protein intended to stimulate antigen-presenting cells and support broader immune responses. Prima BioMed evaluated the therapy in combination with existing cancer treatments, including chemotherapy and immune checkpoint inhibitors, across several solid-tumor indications.
The company conducted clinical-development activities internationally, including in Australia, Europe and the United States.
Further Reading
- Five stocks we like better than Prima BioMed
- Akamai’s Anthropic Deal Puts $5.5 Billion Behind Its Edge AI Pivot
- 3 Stocks Under the Microscope After Large Insider Sales
- The Nasdaq Nears a Major Breakout: 5 Tech ETFs to Play the Move
- AST SpaceMobile’s New Securities Lawsuit Adds Fuel to an Already Volatile Stock
Receive News & Ratings for Prima BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
